Watch our YouTube short first!

Microdosing, the practice of taking small amounts of psychedelic substances, has gained popularity in recent years as a potential treatment for a range of mental health conditions. One area of interest is the use of microdosing for ADHD, a condition that affects millions of people worldwide. Here’s what you need to know about the latest studies:

The Studies

In 2023, a clinical trial was conducted by MindMed, a leading biotech company, to evaluate the safety and efficacy of low-dose LSD as a treatment for ADHD in adults (2). The trial was conducted in collaboration with Maastricht University in the Netherlands, and was led by Dr. Kim Kuypers, one of the leading research experts for microdosing of psychedelics (2). The trial plans to enroll a total of 52 patients that will receive 20µg of LSD every (dose schedule) or placebo for 6 weeks (twice a week on a 3/4-day schedule [± 1 day]) (6). The primary endpoints are mean change from baseline in ADHD symptoms, as assessed by the AISRS after 6 weeks of treatment.

The Potential Benefits

While the results of the clinical trial are not yet available, preliminary research suggests that microdosing may be a promising treatment option for ADHD. A study conducted in 2019 found that microdosers reported improvements in mental health and mood that were generally consistent across the presence of mental health concerns, age, and gender (1). Other studies have suggested that microdosing may improve cognitive function, creativity, and overall well-being (4).

The Risks

It’s important to note that there are still risks associated with the use of psychedelics, even in small doses. While microdosing is generally considered safe, it can still cause side effects such as anxiety, paranoia, and altered perceptions (4). It’s also important to use these substances under the guidance of a qualified medical professional who can monitor your response and ensure your safety.

Conclusion

The use of microdosing for ADHD is an exciting area of research, and the results of the clinical trial conducted by MindMed and Maastricht University are eagerly awaited. While there are still risks associated with the use of psychedelics, the potential benefits are significant, and may offer a new treatment option for those who are struggling with ADHD. If you’re interested in exploring the use of microdosing for your own well-being click here.

References:
1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6753862/
2. https://mindmed.co/news/press-release/mindmed-advances-phase-2-lsd-microdosing-trial-for-adult-adhd-appoints-principal-investigator/
3. https://www.researchgate.net/publication/348277534_Psychedelics_as_a_Potential_Treatment_Option_in_ADHD

4. https://healthyliferecovery.com/microdosing-psilocybin-the-pros-cons-and-unknowns/
5. https://search.proquest.com/openview/c5ee0b57c009e2e6d4015a931d383679/1?cbl=18750&diss=y&pq-origsite=gscholar

6. https://www.prnewswire.com/news-releases/mindmed-initiates-phase-2a-lsd-trial-for-the-treatment-of-adult-adhd-301447252.html

Leave a message

Your email address will not be published. Required fields are marked *

Winkelwagen

X

✅ Shipping to all EU countries | ✅ Support mon-fri 09:00-17:00 | ✅ Free shipping from €99,-

X
en_GB
× Need help?